Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
dc.contributor.author | Manzi, Susan | |
dc.contributor.author | Sánchez-Guerrero, Jorge | |
dc.contributor.author | Merrill, Joan T | |
dc.contributor.author | Furie, Richard | |
dc.contributor.author | Gladman, Dafna | |
dc.contributor.author | Navarra, Sandra V | |
dc.contributor.author | Ginzler, Ellen M | |
dc.contributor.author | D'Cruz, David P | |
dc.contributor.author | Doria, Andrea | |
dc.contributor.author | Cooper, Simon | |
dc.contributor.author | Zhong, Z John | |
dc.contributor.author | Hough, Douglas | |
dc.contributor.author | Freimuth, William | |
dc.contributor.author | Petri, Michelle A | |
dc.date.accessioned | 2023-02-06T20:20:10Z | |
dc.date.available | 2023-02-06T20:20:10Z | |
dc.date.issued | 2012-05-01 | |
dc.identifier.citation | Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov;71(11):1833-8. doi: 10.1136/annrheumdis-2011-200831. Epub 2012 May 1. PMID: 22550315; PMCID: PMC3465857. | en_US |
dc.identifier.eissn | 1468-2060 | |
dc.identifier.doi | 10.1136/annrheumdis-2011-200831 | |
dc.identifier.pmid | 22550315 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12648/8257 | |
dc.description.abstract | To evaluate the effects of belimumab versus placebo, plus standard systemic lupus erythematosus (SLE) therapy, on organ domain-specific SLE disease activity. | |
dc.description.abstract | Data obtained after 52 weeks of treatment from two phase III trials (BLISS-52 and BLISS-76) comparing belimumab 1 and 10 mg/kg versus placebo, plus standard therapy, in 1684 autoantibody-positive patients were analysed post hoc for changes in British Isles Lupus Assessment Group (BILAG) and Safety of Estrogens in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) organ domain scores. | |
dc.description.abstract | At baseline, the domains involved in the majority of patients were musculoskeletal and mucocutaneous by both BILAG and SELENA-SLEDAI, and immunological by SELENA-SLEDAI. At 52 weeks, significantly more patients treated with belimumab versus placebo had improvement in BILAG musculoskeletal and mucocutaneous domains (1 and 10 mg/kg), and in SELENA-SLEDAI mucocutaneous (10 mg/kg), musculoskeletal (1 mg/kg) and immunological (1 and 10 mg/kg) domains. Improvement was also observed in other organ systems with a low prevalence (≤16%) at baseline, including the SELENA-SLEDAI vasculitis and central nervous system domains. Significantly fewer patients treated with belimumab versus placebo had worsening in the BILAG haematological domain (1 mg/kg) and in the SELENA-SLEDAI immunological (10 mg/kg), haematological (10 mg/kg) and renal (1 mg/kg) domains. | |
dc.description.abstract | Belimumab treatment improved overall SLE disease activity in the most common musculoskeletal and mucocutaneous organ domains. Less worsening occurred in the haematological, immunological and renal domains. | |
dc.language.iso | en | en_US |
dc.relation.url | https://ard.bmj.com/content/71/11/1833.long | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. | en_US |
dc.type | Article/Review | en_US |
dc.source.journaltitle | Annals of the rheumatic diseases | en_US |
dc.source.volume | 71 | |
dc.source.issue | 11 | |
dc.source.beginpage | 1833 | |
dc.source.endpage | 8 | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | England | |
dc.description.version | VoR | en_US |
refterms.dateFOA | 2023-02-06T20:20:10Z | |
html.description.abstract | To evaluate the effects of belimumab versus placebo, plus standard systemic lupus erythematosus (SLE) therapy, on organ domain-specific SLE disease activity. | |
html.description.abstract | Data obtained after 52 weeks of treatment from two phase III trials (BLISS-52 and BLISS-76) comparing belimumab 1 and 10 mg/kg versus placebo, plus standard therapy, in 1684 autoantibody-positive patients were analysed post hoc for changes in British Isles Lupus Assessment Group (BILAG) and Safety of Estrogens in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) organ domain scores. | |
html.description.abstract | At baseline, the domains involved in the majority of patients were musculoskeletal and mucocutaneous by both BILAG and SELENA-SLEDAI, and immunological by SELENA-SLEDAI. At 52 weeks, significantly more patients treated with belimumab versus placebo had improvement in BILAG musculoskeletal and mucocutaneous domains (1 and 10 mg/kg), and in SELENA-SLEDAI mucocutaneous (10 mg/kg), musculoskeletal (1 mg/kg) and immunological (1 and 10 mg/kg) domains. Improvement was also observed in other organ systems with a low prevalence (≤16%) at baseline, including the SELENA-SLEDAI vasculitis and central nervous system domains. Significantly fewer patients treated with belimumab versus placebo had worsening in the BILAG haematological domain (1 mg/kg) and in the SELENA-SLEDAI immunological (10 mg/kg), haematological (10 mg/kg) and renal (1 mg/kg) domains. | |
html.description.abstract | Belimumab treatment improved overall SLE disease activity in the most common musculoskeletal and mucocutaneous organ domains. Less worsening occurred in the haematological, immunological and renal domains. | |
dc.description.institution | SUNY Downstate | en_US |
dc.description.department | Rheumatology | en_US |
dc.description.degreelevel | N/A | en_US |
dc.identifier.journal | Annals of the rheumatic diseases |